Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
PTC Therapeutics, Inc.
PTCT
NASDAQ·Healthcare·Biotechnology·Mkt cap $6.7B
$83.31
▲ +2.41%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$43.18 - $87.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 65.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary RNA splicing platform technology enabling targeted genetic medicine development
- Established regulatory expertise in rare disease approvals across multiple jurisdictions
- Commercial infrastructure and partnerships enabling global market access in underserved regions
- First-mover advantage in key rare disease indications with limited competitive alternatives
- Strategic collaborations with pharmaceutical giants (Roche) and disease foundations accelerating R&D
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Moderate growth ahead
Strong revenue growth (115% YoY)
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+20.0% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying PTCT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 23, 2026
MAY 7, 2026
Reported EPS of -$0.03 vs -$0.45 consensus (+93.3% surprise). Revenue of $272.6M vs $217.4M expected (+25.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+93.3%
Next: Apr 23, 2026
Revenue trend · last 8Q
—
—
-31%
+460%
-4%
+7%
-23%
-77%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$186.7M
$196.8M
$213.2M
$1.2B
$178.9M
$211.0M
$164.7M
$272.6M
Margins · last 8Q
Gross
—
Operating
—
Profit
-1.0%
Wall Street consensus
8 analysts · 88% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
88%
Hold
13%
Sell
0%
Median Price Target
$94.00
▲ +12.8% vs $83.31
Latest: Citi · Jun 9, 2026
3 analysts covering